The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
INOVIO Reports Receives FDA Authorization To Proceed With INNOVATE Phase 3 Segment For Its COVID-19 Vaccine Candidate In US
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.
INOVIO Reports Further Expansion Of Its INNOVATE Phase 3 Trial For COVID-19 DNA Vaccine Candidate With Regulatory Authorization From India
Authorization to conduct INNOVATE Phase 3 trial in India builds on recent regulatory authorizations from Brazil, Philippines, Mexico and Colombia
PLYMOUTH MEETING, Pa., Nov. 3, 2021 /PRNewswire/ -- INOVIO
RBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $6
RBC Capital analyst Gregory Renza maintains Inovio Pharmaceuticals (NASDAQ:INO) with a Sector Perform and lowers the price target from $7 to $6.
AstraZeneca’s Medimmune Terminates DNA Cancer Vaccine Program With Inovio
MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ:AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ:INO) to terminate the DNA cancer vaccine development program agreement. Under…
Inovio Pharmaceuticals Granted US Patent Titled ‘Cancer vaccines targeting mesothelin and uses thereof’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6188&f=G&l=50&d=PTXT&p=124&S1=20211026&OS=20211026&RS=20211026
Inovio Pharmaceuticals Announces Collaboration With Colombia On Memorandum Of Understanding Focusing On Protecting Against COVID-19 And Supporting Broader Health Preparedness Initiatives
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced the
INOVIO Expands INNOVATE Phase 3 For INO-4800, Its DNA Vaccine Candidate For COVID-19, To Include Colombia Following Regulatory Authorization
INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that
Looking Into Inovio Pharmaceuticals’s Return On Capital Employed
Inovio Pharmaceuticals (NASDAQ:INO) brought in sales totaling $272.82 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 58.32%, resulting in a loss of $83.20 million.